Park National Corp’s Novartis NVS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$2.21M Sell
14,119
-44
-0.3% -$6.6K 0.06% 156
2026
Q1
$2.16M Buy
14,163
+1,183
+9% +$181K 0.07% 158
2025
Q4
$1.79M Sell
12,980
-523
-4% -$68.5K 0.06% 151
2025
Q3
$1.73M Sell
13,503
-252
-2% -$30.8K 0.05% 151
2025
Q2
$1.66M Sell
13,755
-90
-0.7% -$10.1K 0.05% 148
2025
Q1
$1.54M Sell
13,845
-943
-6% -$100K 0.06% 148
2024
Q4
$1.44M Sell
14,788
-158
-1% -$16.8K 0.05% 148
2024
Q3
$1.72M Sell
14,946
-404
-3% -$45.8K 0.06% 143
2024
Q2
$1.63M Sell
15,350
-684
-4% -$68.7K 0.06% 142
2024
Q1
$1.55M Sell
16,034
-1,878
-10% -$193K 0.06% 143
2023
Q4
$1.81M Sell
17,912
-497
-3% -$48K 0.07% 132
2023
Q3
$1.88M Sell
18,409
-442
-2% -$44.9K 0.08% 128
2023
Q2
$1.9M Sell
18,851
-679
-3% -$67.9K 0.08% 126
2023
Q1
$1.8M Sell
19,530
-1,183
-6% -$103K 0.08% 131
2022
Q4
$1.88M Sell
20,713
-1,978
-9% -$167K 0.08% 131
2022
Q3
$1.72M Sell
22,691
-910
-4% -$75.4K 0.09% 119
2022
Q2
$2M Sell
23,601
-3,784
-14% -$332K 0.1% 116
2022
Q1
$2.4M Sell
27,385
-4,202
-13% -$364K 0.1% 113
2021
Q4
$2.76M Sell
31,587
-10,872
-26% -$903K 0.11% 108
2021
Q3
$3.47M Sell
42,459
-1,806
-4% -$162K 0.15% 99
2021
Q2
$4.04M Sell
44,265
-14,076
-24% -$1.25M 0.17% 92
2021
Q1
$4.99M Sell
58,341
-20,524
-26% -$1.84M 0.22% 86
2020
Q4
$7.45M Sell
78,865
-3,602
-4% -$315K 0.35% 72
2020
Q3
$7.17M Sell
82,467
-18,799
-19% -$1.63M 0.38% 69
2020
Q2
$8.84M Sell
101,266
-23,422
-19% -$2.02M 0.5% 59
2020
Q1
$10.3M Sell
124,688
-8,641
-6% -$771K 0.65% 47
2019
Q4
$12.6M Sell
133,329
-2,100
-2% -$188K 0.64% 48
2019
Q3
$11.8M Sell
135,429
-7,742
-5% -$695K 0.64% 45
2019
Q2
$13.1M Sell
143,171
-68,682
-32% -$5.81M 0.71% 39
2019
Q1
$18.3M Sell
211,853
-39,901
-16% -$3.2M 1.03% 30
2018
Q4
$19.4M Sell
251,754
-52,300
-17% -$4.07M 1.2% 28
2018
Q3
$23.5M Sell
304,054
-36,049
-11% -$2.66M 1.29% 25
2018
Q2
$23M Buy
340,103
+6,863
+2% +$474K 1.32% 26
2018
Q1
$24.1M Sell
333,240
-2,882
-0.9% -$219K 1.4% 24
2017
Q4
$25.3M Sell
336,122
-4,237
-1% -$320K 1.41% 25
2017
Q3
$26.2M Buy
340,359
+7,914
+2% +$598K 1.5% 20
2017
Q2
$24.9M Buy
332,445
+3,381
+1% +$240K 1.48% 22
2017
Q1
$21.9M Buy
329,064
+16,873
+5% +$1.12M 1.32% 26
2016
Q4
$20.4M Buy
312,191
+8,949
+3% +$581K 1.24% 26
2016
Q3
$21.5M Buy
303,242
+2,615
+0.9% +$191K 1.37% 22
2016
Q2
$22.2M Buy
300,627
+3,489
+1% +$241K 1.42% 23
2016
Q1
$19.3M Buy
297,138
+17,888
+6% +$1.22M 1.28% 25
2015
Q4
$21.5M Buy
279,250
+5,298
+2% +$421K 1.46% 22
2015
Q3
$22.6M Buy
273,952
+8,092
+3% +$720K 1.62% 18
2015
Q2
$23.4M Buy
265,860
+4,367
+2% +$401K 1.6% 19
2015
Q1
$23.1M Buy
261,493
+10,062
+4% +$892K 1.57% 19
2014
Q4
$20.9M Buy
251,431
+14,880
+6% +$1.23M 1.38% 24
2014
Q3
$20M Buy
236,551
+11,766
+5% +$952K 1.45% 23
2014
Q2
$18.2M Buy
224,785
+26,691
+13% +$2.1M 1.25% 23
2014
Q1
$15.1M Buy
198,094
+28,431
+17% +$2.07M 1.07% 27
2013
Q4
$12.2M Buy
169,663
+11,969
+8% +$832K 0.87% 34
2013
Q3
$10.8M Buy
157,694
+17,971
+13% +$1.19M 0.83% 36
2013
Q2
$8.85M Buy
+139,723
New +$9.09M 0.72% 38

Other funds holding NVS

Park National Corp's NVS Position: Q2 2026 in Review

Park National Corp reduced its Novartis (NVS) stake by 0.31% in Q2 2026, selling an estimated $6.6K and leaving 14,119 shares worth $2.21M. The position accounts for 0.06% of the portfolio, ranked #156.

Park National Corp first reported a position in NVS in Q2 2013 and has held it in 53 quarters since. The position peaked at $26.2M in Q3 2017. 693 funds tracked by Wall St. Rank hold NVS as of Q2 2026.

  • Park National Corp held 14,119 shares of Novartis worth $2.21M as of Q2 2026.
  • Park National Corp sold 44 Novartis shares in Q2 2026, an estimated $6.6K.
  • Novartis made up 0.06% of Park National Corp's portfolio in Q2 2026, its #156 holding.
  • Park National Corp first reported a position in Novartis in Q2 2013 and has held it in 53 quarters since.
  • Park National Corp's Novartis position peaked at $26.2M in Q3 2017.
  • 693 funds tracked by Wall St. Rank held Novartis as of Q2 2026.

Based on Park National Corp's 13F filing for Q2 2026, filed 15 Jul 2026.